Patient considerations in cataract surgery - the role of combined therapy using phenylephrine and ketorolac.
Cataract, a degradation of the optical quality of the crystalline lens, progressive and age-related, is the leading cause of treatable blindness worldwide. Cataract surgery is the most common surgical procedure performed by ophthalmologists and is the only effective treatment for cataracts. Advances in the surgical techniques and better postoperative visual outcomes have progressively changed the primary concern of cataract surgery to become a procedure refined to yield the best possible refractive results. Sufficient mydriasis during cataract removal is critical to a successful surgical outcome. Poor pupil dilation can lead to serious sight-threatening complications that significantly increase the cost of surgery and decrease patients comfort. Mydriasis is obtained using anticholinergic and sympathomimetic drugs. Phenylephrine, an α1-adrenergic receptor agonist, can efficiently dilate the pupil when administered by intracameral injection. Additionally, nonsteroidal anti-inflammatory drugs (NSAIDs) like ketorolac, which inhibit the synthesis of prostaglandins, are used to decrease intraoperative miosis, control pain and inflammation associated with cataract surgery, and to prevent the development of cystoid macular edema following surgery. Recently, a new combination of phenylephrine and ketorolac (Omidria®) has been approved by United States Food and Drug Administration for use during cataract surgery to maintain intraoperative mydriasis, prevent miosis, and reduce postoperative pain and inflammation. Clinical trials have shown that this new combination is effective, combining the positive effects of both drugs with a good safety profile and patient tolerability. Moreover, recent reports suggest that this combination is also effective in patients with high risk of poor pupil dilation. In conclusion, cataract is a global problem that significantly affects patients' quality of life. However, they can be managed with a safe and minimally invasive surgery. Advances in surgical techniques and newer pharmacological agents such as the combination of phenylephrine and ketorolac, together with better intraocular lenses, have greatly improved visual outcomes and thus patients' expectations regarding visual recovery are also increasing.
Department of Biomedical Research, Universidad Autónoma de Querétaro, Querétaro, Mexico; Department of Research, Asociación para Evitar la Ceguera en México, Mexico City, Mexico.
Roberto
R
Gonzalez-Salinas
Department of Ophthalmology, Clínica Universidad de Navarra, Pamplona, Spain.
Adriano
A
Guarnieri
Department of Ophthalmology, Clínica Universidad de Navarra, Pamplona, Spain.
María Concepción
MC
Guirao Navarro
Department of Ophthalmology, Clínica Universidad de Navarra, Pamplona, Spain.
Manuel
M
Saenz-de-Viteri
Omidria®; cataract surgery; ketorolac; mydriasis; phenylephrine
Clin Ophthalmol. 2016 Jan 19;10:151-9
26855559
Acta Ophthalmol. 2015 May;93(3):293-8
24975543
Acta Ophthalmol Scand. 2004 Apr;82(2):144-7
15043530
J Cataract Refract Surg. 2003 Mar;29(3):423
12662990
Cochrane Database Syst Rev. 2015 Nov 02;(11):CD004242
26524611
J Cataract Refract Surg. 2012 Dec;38(12):2144-53
23084599
J Cataract Refract Surg. 2002 Jan;28(1):93-9
11777716
Surv Ophthalmol. 2014 Nov-Dec;59(6):579-98
25127929
Ophthalmology. 2015 Nov;122(11):2159-68
26123091
J Cataract Refract Surg. 2016 Feb;42(2):310-28
27026457
Br J Ophthalmol. 2004 Oct;88(10):1242-6
15377542
Ophthalmology. 2012 Oct;119(10):2053-8
22709418
Clin Exp Ophthalmol. 2011 Jul;39(5):456-61
21070540
Clin Ophthalmol. 2015 Jul 10;9:1249-54
26203214
J Cataract Refract Surg. 2007 Nov;33(11):1925-9
17964399
J Cataract Refract Surg. 2009 Oct;35(10):1688-93
19781460
Indian J Ophthalmol. 2015 Oct;63(10 ):775-8
26655002
J Cataract Refract Surg. 2015 Apr;41(4):719-23
25840296
Eye (Lond). 2014 Oct;28(10):1267-8
25033903
Clin Ophthalmol. 2013;7:1429-35
23885165
PLoS One. 2014 Apr 18;9(4):e94140
24747192
PLoS One. 2016 Jan 07;11(1):e0144853
26741363
Cornea. 2015 Apr;34(4):460-3
25474237
Acta Ophthalmol. 2014 Aug;92(5):482-5
23981528
Clin Ophthalmol. 2014 Sep 05;8:1735-44
25228791
Eye Vis (Lond). 2015 Apr 30;2:8
26613089
Eye (Lond). 2015 Apr;29(4):552-60
25679413
Sao Paulo Med J. 2015 Feb;133(1):68
25626855
J Cataract Refract Surg. 2009 Oct;35(10):1679-87.e1
19781459
J Cataract Refract Surg. 2008 Feb;34(2):280-3
18242454
Curr Opin Ophthalmol. 2015 Jan;26(1):3-9
25390859
Eye Vis (Lond). 2015 Jan 31;2:2
26605358
J Cataract Refract Surg. 2003 Dec;29(12):2378-84
14709300
Int J Ophthalmol. 2013 Dec 18;6(6):801-4
24392328
Am J Ophthalmol. 1987 Apr 15;103(4):479-86
3551617
Ophthalmology. 1999 Sep;106(9):1656-9
10485530
Med Arch. 2014;68(2):117-20
24937936
Br J Ophthalmol. 2007 Apr;91(4):470-5
17124243
Ophthalmology. 2016 Feb;123(2):316-23
26681390
Ann Pharmacother. 2015 Jun;49(6):727-34
25725037
J Cataract Refract Surg. 2002 Mar;28(3):517-20
11973101
J Cataract Refract Surg. 2009 Feb;35(2):273-6
19185242
Clin Ophthalmol. 2014 Jul 03;8:1281-9
25061276
J Ophthalmic Vis Res. 2015 Jul-Sep;10(3):250-6
26730309
J Ophthalmol. 2015;2015:383456
26064671
Biochim Biophys Acta. 2016 Jan;1860(1 Pt B):192-8
26318017
J Cataract Refract Surg. 2015 Oct;41(10):2060-8
26703280
Retina. 2012 Nov-Dec;32(10):2158-64
23099451
Indian J Ophthalmol. 2014 Feb;62(2):103-10
24618482
Ophthalmology. 2000 Nov;107(11):2034-8;discussion 2039
11054327
Can J Ophthalmol. 2013 Aug;48(4):251-8
23931462
Clin Ther. 1999 Apr;21(4):723-32
10363737
Int J Ophthalmol. 2015 Dec 18;8(6):1173-8
26682168